Extended Platelet Rich Fibrin in Mandibular Alveolar Ridge Splitting

Extended Platelet Rich Fibrin in Mandibular Alveolar Ridge Splitting With Simultaneous Implant Placement

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06637982

Enrollment

Registered

2024-10-15

Start date

2024-10-10

Completion date

2025-10-10

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ridge Splitting

Brief summary

Thirty two healthy implants will be selected from the outpatient clinic of the oral and maxillofacial department of Mansoura university to be included in this study for replacement of lost posterior teeth with limited bone width.

Interventions

PROCEDUREridge splitting with the use of allograft and pericardium membrane

ridge splitting with the use of allograft and pericardium membrane

PROCEDUREridge splitting with the use of extended platelet rich fibrin

ridge splitting with the use of extended platelet rich fibrin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patient age 18 years old and older. * Patient's cooperation, motivation and good oral hygiene. * Atrophic posterior mandible of horizontal alveolar dimension range between 3 - 6 mm at the crest, with minimum 10 mm vertical height from the alveolar crest to the superior border of the inferior alveolar canal. * Absence of undercuts in buccal aspect of the ridge. * Favorable occlusion and no parafunctional habits. * Patients able to comply with the required recall visits. * No gender preface in selection of the patients. * Acceptable inter-arch space for the future prosthesis.

Exclusion criteria

* Any pathological condition at the site of surgery. * Patients with systemic diseases that contra-indicate the surgical procedure such as uncontrolled diabetes mellitus, bleeding disorders, serious osseous disorders, and mental disorders. * Patient taking drugs that could affect bone healing process as immunosuppressive drugs and bisphosphonates. * Heavy smoking and alcoholism. * Parafunctional habits such as bruxism and clenching. * Signs of acute infection or pus discharge. * Untreated periodontal disease or bad oral hygiene.

Design outcomes

Primary

Measure	Time frame	Description
implant stability	9 months	the stability of the implants will be evaluated by RFA with the Osstell Mentor device
alveolar ridge width	9 months	alveolar ridge width will be measured preoperative, immediate postoperative and after 9 months

Countries

Egypt

Contacts

Primary Contactfaisal alshammri

fasialshammry@std.mans.edu.eg1555250898

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026